Mark Jacobson, MD

Headshot of Mark Jacobson
User Profile Photo

Mark Jacobson, MD

User Profile Name
Emeritus CFAR Mentor
Professor, School of Medicine
User Profile Title
User Profile Email


Dr. Jacobson is a clinician, educator, and researcher who has specialized in HIV/AIDS and its complications since joining the UCSF faculty in 1986. His earlier career involved leading multicenter, interventional trials that focused on developing effective treatments for AIDS-associated opportunistic infections. His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He now teaches medicine residents and medical students, provides clinical care and directs urgent care medical services for the Ward 86 HIV clinic at San Francisco General Hospital, and is the editor for the Ward 86 Medical Management Recommendations posted on UCSF’s HIV InSite website. Dr. Jacobson is also the author of Sensing Light, a novel about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see In March, 2020, Dr. Jacobson was redeployed to Occupational Medicine division and in July, 2020, moved from the HIV/ID division to the Occupational Medicine, where he serves as the infectious diseases consultant for a team of MDs, NPs and RNs who manage employee COVID-19 health issues for all SF Department of Public Health facilities, including SF General Hospital. He currently staffs the Occupational Health Service COVID-19 and Vaccine Hotlines, has created and updates Hotline provider standard work guidance for testing/off-return to work decisions/management of COVID-19 vaccine adverse events, teaches Hotline providers, consults with Occupational Medicine leadership re policy changes and special issues that arise, and oversees a Vaccine Hotline, which he helped develop in December, 2020, for management of employees experiencing adverse effects of COVID-19 vaccination.
CTSI Profile Bio

Displaying 1 - 25 of 136

  1. Jacobson M, Hart C, Huen W, Suarez Guardado G, Villanueva A, Whitman J, Blanc PD. A Rapid Nucleic-Acid-Amplification-Test-Based, Conditional-Release-to-Work Policy for Health Care Personnel with Symptoms Consistent with COVID-19. J Occup Environ Med. 2022 Oct 17.
  2. Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 07; 179(7):490-499.
  3. A. Zakaria, K. Abuabara, P. Kim-Lim, L. Fox, E. Amerson, A. Chang. LB737 Lack of stable housing as a risk factor for group A streptococcal skin and soft tissue infection among hospitalized adult patients. Journal of Investigative Dermatology. 2021 Sep 1; 141(9):b9.
  4. Maung Z, Kristensen M, Hoffman B, Jacobson MA. Temperature Screening of Healthcare Personnel Is Ineffective in Controlling COVID-19. J Occup Environ Med. 2022 05 01; 64(5):382-384.
  5. Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT, Overton ET. Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. AIDS. 2018 06 19; 32(10):1279-1287.
  6. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS. 2016 06 19; 30(10):1573-82.
  7. Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. J Acquir Immune Defic Syndr. 2014 May 01; 66(1):25-32.
  8. Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One. 2013; 8(11):e78676.
  9. Meyer AC, Jacobson M. Asymptomatic cryptococcemia in resource-limited settings. Curr HIV/AIDS Rep. 2013 Sep; 10(3):254-63.
  10. Jacobson M, Lurain N, Hunt P. Cytomegalovirus viraemia in the modern antiretroviral era(*). HIV Med. 2011 Aug; 12(7):387-8.
  11. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474-83.
  12. Hartigan-O'Connor DJ, Jacobson MA, Tan QX, Sinclair E. Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17 cell depletion and poor systemic CMV-specific T cell responses. Clin Infect Dis. 2011 Feb 01; 52(3):409-17.
  13. Jagannathan P, Davis E, Jacobson M, Huang L. Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS. 2009 Aug 24; 23(13):1794-6.
  14. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun; 10(3):143-52.
  15. Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. PLoS One. 2009; 4(4):e5277.
  16. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 2009 Mar 04; 27(10):1540-8.
  17. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008 Oct 01; 49(2):231-3.
  18. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis. 2008 Feb 01; 46(3):458-66.
  19. Jacobson MA. Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS? PLoS Med. 2007 Mar 27; 4(3):e110.
  20. Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J Infect Dis. 2006 Dec 01; 194(11):1537-46.
  21. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine. 2006 Jun 19; 24(25):5311-9.
  22. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol. 2006 Mar; 35(3):332-7.
  23. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53.
  24. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005 May; 112(5):771-9.
  25. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005 May-Jun; 6(3):136-46.